Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1084617 | PMC |
| http://dx.doi.org/10.1073/pnas.12.7.424 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between multimorbidity and postoperative mortality in patients undergoing major surgery: a prospective study in 29 countries across Europe.
Anaesthesia
September 2024
Academic Department of Surgery, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Background: Multimorbidity poses a global challenge to healthcare delivery. This study aimed to describe the prevalence of multimorbidity, common disease combinations and outcomes in a contemporary cohort of patients undergoing major abdominal surgery.
Methods: This was a pre-planned analysis of a prospective, multicentre, international study investigating cardiovascular complications after major abdominal surgery conducted in 446 hospitals in 29 countries across Europe.
Impact of postoperative cardiovascular complications on 30-day mortality after major abdominal surgery: an international prospective cohort study.
Anaesthesia
July 2024
Academic Department of Surgery, Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TH, United Kingdom.
Cardiovascular complications after major surgery are associated with increases in morbidity and mortality. There is confusion over definitions of cardiac injury or complications, and variability in the assessment and management of patients. This international prospective cohort study aimed to define the incidence and timing of these complications and to investigate their impact on 30-day all-cause mortality.
View Article and Find Full Text PDFBackground: Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess the effect of intravenous immunoglobulin or corticosteroids compared with usual care on duration of hospital stay for children with PIMS-TS and to compare tocilizumab (anti-IL-6 receptor monoclonal antibody) or anakinra (anti-IL-1 receptor antagonist) with usual care for those with inflammation refractory to initial treatment.
Methods: We did this randomised, controlled, open-label, platform trial in 51 hospitals in the UK.
Article Synopsis
- A study evaluated the effects of a higher dose of corticosteroids on COVID-19 patients who needed oxygen or ventilatory support, building on previous findings that low-dose corticosteroids reduced mortality in similar patients.
- The research was part of the RECOVERY trial, which randomly assigned patients to receive either higher dose corticosteroids or usual care with a lower dose, measuring 28-day mortality rates as the primary outcome.
- From May 2021 to May 2022, 1,272 patients were included, with notable participation from Asia and the UK; results showed that nearly all of the patients who received usual care also received some form of low-dose corticosteroids.
Background: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1-2 inhibitor, for the treatment of patients admitted to hospital with COVID-19.
Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised with COVID-19 in the UK. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!